6/23/2009

GlaxoSmithKline is teaming up with Chroma Therapeutics to secure rights to the latter's small-molecule compounds that target macrophages to treat inflammatory diseases such as rheumatoid arthritis. Chroma could receive more than $1 billion out of the deal depending on the success of the four drug programs, which employ its proprietary esterase-sensitive motif technology to enhance drug delivery.

Full Story:
Reuters

Related Summaries